ClinicalTrials.gg
CompletedNCT04091880Updated Oct 12, 2022

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

A Phase 4 interventional study of EV71 vaccine and influenza vaccine and EV71 vaccine in Enterovirus Infections and Influenza, sponsored by China National Biotec Group Company Limited. Completed at 1 site in China. Open to participants aged 6 Months to 11 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by China National Biotec Group Company Limited (part of Sinopharm) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,134
Allocation
Randomized
Ages
6 Months to 11 Months
Sex
All
01

Study summary

Subjects will be recruited and divided into 3 groups:

  1. Experimental Group (378 subjects): combined immunization of EV71 vaccine and influenza vaccine;
  2. Control Group A (378 subjects): EV71 vaccine only;
  3. Control Group B (378 subjects): influenza vaccine only;

All blood samples will be collected before and one month after vaccinatioin. The immunogenicity and safety of both experimental and control groups will be compared and the data be analyzed.

Read the detailed description

To further evaluate the feasibility of simultaneously administration of EV71 vaccine and flu vaccine, we design this clinical trial to test its immunogenicity and safety. 1134 subjects aged from 6 to 11 months old are divided into one experimental group and two control groups (control group A and B).

378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously. Blood samples are collected before the first vaccination, and one month following the second vaccination.

378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart). Blood samples are collected before the first vaccination, and one month following the second vaccination.

378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart). Blood samples are collected before the first vaccination, and one month following the second vaccination.

To evaluate the immunogenicity, we will detect and compare the neutralization antibody levels, the seroprotection rates, and antibody geometric mean concentrations. The safety of all groups will be monitored as well.

02

Conditions studied

  • Enterovirus Infections
  • Influenza

Keywords

  • EV71 vaccine
  • influenza vaccine
  • simultaneously administration
03

In context

Enterovirus Infections

48 studies on the registry are indexed under Enterovirus Infections; 3 are open to participants now.

This study's enrollment of 1,134 is above the median of 132 across 31 interventional studies indexed under Enterovirus Infections.

Browse Enterovirus Infections studies →

Lead sponsor

China National Biotec Group Company Limited is the lead sponsor of 37 studies on the registry; 2 are open to participants now.

First submitted after China National Biotec Group Company Limited became part of Sinopharm.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 11 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects aged from 6-11 months old at the date of recruitment;
  • with signed by parent(s) or guardians;
  • parent(s) or guardians are able to attend all planned clinical appointments and comply with all study instructions;
  • subjects not receive any vaccination within 14 days at the date of recruitment;
  • subjects have not been vaccinated with EV71 vaccine, seasonal flu vaccine;
  • subjects with no medical history of EV71 infection;
  • axillary temperature ≤37.0℃

Exclusion criteria

Exclusion Criteria:

  • subject who has a medical history with Hypersensitiveness, eclampsia, epilepsy, cerebropathia and neurological illness;
  • allergic to any ingredient of vaccine or with allergy history to any vaccine;
  • subjects with immunodeficency or suspected impairment of immunologic function (e.g. caused by ), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of hormone);
  • administration of immunoglobulins within 30 days prior to this study;
  • acute febrile disease(temperature ≥ 37.0°C) or infectious disease;
  • have a clearly diagnosed history of thrombocytopenia or other coagulopathy,
  • may cause for subcutaneous injection;
  • any serious chronic illness, acute infectious diseases, or respiratory diseases;
  • severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with complications;
  • any kind of infectious, purulent, or allergic skin diseases;
  • any other factor that makes the investigator determines the subject is unsuitable for this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,134 participants (actual)

Study arms

  • Experimental
    experimental group

    378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.

    Biological: EV71 vaccine and influenza vaccine

  • Active comparator
    control group A

    378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).

    Biological: EV71 vaccine

  • Active comparator
    control group B

    378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).

    Biological: influenza vaccine

Interventions

  • BiologicalEV71 vaccine and influenza vaccine

    Drug page: EV71

    simultaneously administrated with EV71 vaccine and influenza vaccine

  • BiologicalEV71 vaccine

    administrated with EV71 vaccine only

  • Biologicalinfluenza vaccine

    administrated with influenza vaccine only

06

What researchers measure

Primary outcomes

  1. Seroconversion rate I

    the rate of positive seroconversion against EV71

    Time frame: Baseline (before vaccination) and 1 month after the last dose

  2. Seroconversion rate II

    the rate of positive seroconversion against Influenza A (H3N2, H1N1) and B Type viruses

    Time frame: Baseline (before vaccination ) and 1 month after the last dose

  3. Geometric mean titer (GMT) I

    Measure neutralizing antibody titers against EV71

    Time frame: Baseline (before vaccination) and 1 month after the last dose

  4. Geometric mean titer (GMT) II

    Measure neutralizing antibody titers against Influenza A (H3N2, H1N1) and B Type viruses

    Time frame: Baseline (before vaccination) and 1 month after the last dose

Secondary outcomes

  1. adverse events following vaccination

    analyse the numbers and rates of participants who experience adverse events following immunization

    Time frame: 6 months

07

Study locations

1 site
  • Zhejiang provincial center for disease control and prevention
    Hangzhou, Zhejiang 310051, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Jan 2020, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2019
First posted
Sep 17, 2019
StartActual
Sep 26, 2019
Primary completionActual
Jan 6, 2020
CompletionActual
Aug 10, 2021
Last update
Oct 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04091880
Collaborators
Zhejiang Provincial Center for Disease Control and Prevention, Henan Center for Disease Control and Prevention, Guizhou Center for Disease Control and Prevention, Wuhan Institute of Biological Products Co., Ltd, Changchun Institute of Biological Products Co., Ltd., Peking University, National Institutes for Food and Drug Control, China
Responsible party
Sponsor
First posted
Sep 17, 2019
Start date
Sep 26, 2019
Primary completion
Jan 6, 2020
Completion
Aug 10, 2021
Last update
Oct 12, 2022

Study contacts

Hanqing He
principal investigator · Zhejiang Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EV71

Start the discussion